Xiamen Amoytop Biotech Hits Day High with Strong 4.48% Intraday Surge

Xiamen Amoytop Biotech Co. has experienced a notable increase of 4.48% on July 20, 2026, reaching an intraday high of CNY 60.30. This performance stands out against the backdrop of the China Shanghai Composite, which only rose by 0.85% on the same day. Over the past week, Xiamen Amoytop has shown a robust gain of 7.82%, significantly outperforming the broader market, which declined by 3.0%. Despite a challenging year, with a year-to-date performance of -28.17%, the company has consistently reported positive results for the last 18 consecutive quarters. Key financial metrics indicate a strong operational foundation, with net sales reaching a record CNY 1,216.02 million and an operating profit of CNY 472.2 million. The company's return on equity stands at an impressive 34.50%, and it maintains a healthy interest coverage ratio, reflecting minimal interest costs. Xiamen Amoytop's market capitalization is CNY 23,330 million, positioning it as a large-cap player in the pharmaceuticals and biotechnology sector. The stock's current dividend yield is 1.08%, further highlighting its financial stability amidst market fluctuations.